Latest research
Latest corporate research
Latest tax enhanced reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact Us
Twitter icon
Created with Sketch.
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax enhanced research
Product reports for investors and advisors
Latest published research
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Services for private Companies
Tax enhanced research
Product reports for investors and advisors.
Bespoke consulting services
Bespoke services
Services for clients with specific needs
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
24: Making big ideas investible and measuring impact | Dan Somers of Boundary Capital
Stay up-to-date with the latest research
Sign up to our newsletter
COVID-19: -
Our Commitment to Client Service & Investor Communications
Life Sciences research
ValiRx
Life Sciences
Initiation: Developing novel cancer therapies
By
Dr Dorothea Hill
31 May 2017
Alliance Pharma Plc
Life Sciences
A transformational year driving growth
By
Dr Martin Hall
25 May 2017
Stay up-to-date with the latest research
Sign up to our newsletter
Avacta Group plc
Life Sciences
Affimers 2 – Antibodies 0
By
Dr Martin Hall
24 May 2017
Collagen Solutions Plc
Life Sciences
Trading update indicates earnings above forecasts
By
Dr Martin Hall
11 May 2017
Avacta Group plc
Life Sciences
De-risking of the partnership with Moderna
By
Dr Martin Hall
08 May 2017
Avacta Group plc
Life Sciences
Bringing forward the Affimer technology
By
Dr Martin Hall
05 May 2017
Avacta Group plc
Life Sciences
Another important box ticked
By
Dr Martin Hall
12 Apr 2017
Redx Pharma
Life Sciences
CARB-X – new strategic collaboration
By
Dr Martin Hall
03 Apr 2017
Oxford BioMedica
Life Sciences
Initiation: Delivering commercial gene-therapy vector
By
Dr Dorothea Hill
31 Mar 2017
Diurnal Group Plc
Life Sciences
Commercial and development progresses
By
Dr Martin Hall
27 Mar 2017
Avacta Group plc
Life Sciences
Low response would be positive!
By
Dr Gregoire Pave
21 Mar 2017
Prev
1
...
14
15
16
17
Next
